Fig. 3From: Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART studyChange of EDSS between baseline and visit 3, at 12 months vs number of 12-month pre-treatment relapses (n = 47) (a) and 12-month post-treatment relapses (n = 47) (b). The size of the bubbles represents the number of observations at each point on the graphBack to article page